You are here
Scheduling delegate's interim decisions and invitation for further comment: ACCS/ACMS, March and July 2017
Scheduling medicines and poisons
15 September 2017
1. Summary of delegate's interim decisions
Advisory Committee on Medicines Scheduling (ACMS #21)
| Substance | Interim decision |
|---|---|
| Sildenafil | The delegate's interim decision is that the current scheduling of sildenafil remains appropriate. |
| Vardenafil | The delegate's interim decision is that the current scheduling of vardenafil remains appropriate. |
| Ibuprofen combined with paracetamol | The delegate's interim decision is that the current scheduling of ibuprofen combined with paracetamol remains appropriate. |
| Esomeprazole | Schedule 4 – Amend Entry ESOMEPRAZOLE except when included in Schedule 2. Schedule 3 – Delete Entry Schedule 2 – Amend Entry ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply. |
| Stiripentol |
Appendix K – New Entry STIRIPENTOL The proposed implementation date is 1 February 2018. |